Continued low-dose decitabine (DAC) is an active first-line treatment.: In all cytogenetic subgroups of older AML patients:: Results of the FR00331 multicenter phase II study

被引：9
|
作者：
Luebbert, Michael [1 ]
Rueter, Bjorn [1 ]
Claus, Rainer
Schmid, Mathias [2 ]
Germing, Ulrich [3 ]
Eimeracher, Hartmut [4 ]
Ganser, Arnold [5 ]
Platzbecker, Uwe [6 ]
Galm, Oliver [7 ]
Brugger, Wolfram [8 ]
Heil, Gerhard [9 ]
Wijermans, Pierre W. [10 ]
Pfeifer, Dietmar [1 ]
Schmoor, Claudia [11 ]
Doehner, Hartmut [2 ]
机构：
[1] Univ Hosp, Freiburg, Germany
[2] Univ Hosp, Ulm, Germany
[3] Univ Hosp, Dusseldorf, Germany
[4] Catholic Hosp, Hagen, Germany
[5] Univ Hosp, Hannover, Germany
[6] Univ Hosp, Dresden, Germany
[7] Univ Hosp, Aachen, Germany
[8] Hospital, Villigen Schwenningen, Germany
[9] Hospital, Ludenscheid, Germany
[10] Leyenburg Hosp, The Hague, Netherlands
[11] Univ Hosp, Ctr Clin Trials, Freiburg, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.300.300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
300
引用
收藏
页码：95A / 95A
页数：1
相关论文
共 50 条
  • [11] Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS)
    Macdonald, D. A.
    Assouline, S. E.
    Brandwein, J.
    Kamel-Reid, S.
    Eisenhauer, E. A.
    Couban, S.
    Foo, A.
    Leber, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [12] A multicenter phase II study of epirubicin with low-dose trastuzumab as a first line treatment in Her-2 overexpressing metastatic breast cancer: preliminary results
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 165 - 165
  • [13] Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)
    Blum, William
    Klisovic, Rebecca
    Liu, Shujun
    Garzon, Ramiro
    Kefauver, Cheryl
    Liu, Zhongfa
    Mickle, Jon
    Devine, Hollie
    Devine, Steve
    Grever, Michael R.
    Chan, Kenneth K.
    Villalona-Calero, Miguel
    Byrd, John C.
    Marcucci, Guido
    BLOOD, 2008, 112 (11) : 1016 - 1016
  • [14] A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer
    De Tursi, M.
    Carella, C.
    Ricevuto, E.
    Gennari, A.
    Orlandini, C.
    Frassoldati, A.
    Conte, P. F.
    Iacobelli, S.
    BREAST, 2007, 16 : S41 - S41
  • [15] A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC)
    De Tursi, M.
    Carella, C.
    Ricevuto, E.
    Gennari, A.
    Orlandini, C.
    Frassoldati, A.
    Conte, P. F.
    Iacobelli, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [16] A phase II trial of split, low-dose docetaxel and low-dose capecitabine:: A tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer
    Silva, Orlando
    Lopes, Gilberto
    Morgenzstern, Daniel
    Lobo, Christopher
    Doliny, Philomena
    Santos, Edgardo
    Abdullah, Sakher
    Gautam, Umang
    Reis, Isildinha
    Welsh, Catherine
    Slingerland, Joyce
    Hurley, Judith
    Gluck, Stefan
    CLINICAL BREAST CANCER, 2008, 8 (02) : 162 - 167
  • [17] A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
    Fujimoto, D.
    Yokoyama, T.
    Yoshioka, H.
    Demura, Y.
    Hirano, K.
    Kawai, T.
    Kagami, R.
    Ishida, T.
    Tomii, K.
    Akai, M.
    Hirabayashi, M.
    Nishimura, T.
    Nakahara, Y.
    Kim, Y. H.
    Yoshimura, K.
    Hirai, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [18] Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group
    Becker, Heiko
    Suciu, Stefan
    Rueter, Bjorn
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Labar, Boris
    Germing, Ulrich
    Salih, Helmut R.
    Muus, Petra
    Pfluger, Karl-Heinz
    Hagemeijer, Anne
    Schaefer, Hans-Eckart
    Baron, Frederic
    Ganser, Arnold
    Aul, Carlo
    de Witte, Theo
    Wijermans, Pierre W.
    Luebbert, Michael
    BLOOD, 2013, 122 (21)
  • [19] A multicenter Phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results
    De Tursi, M.
    Carella, C.
    Ricevuto, E.
    Marchetti, P.
    Gennari, A.
    Orlandini, C.
    Frassoldati, A.
    Conte, P.
    Iacobelli, S.
    EJC SUPPLEMENTS, 2005, 3 (02): : 116 - 116
  • [20] A PILOT STUDY OF LOW-DOSE CAPECITABINE PLUS TRASTUZUMAB AS FIRST-LINE TREATMENT IN PATIENTS AGED 75 YEARS OR OLDER WITH HER2-POSITIVE ADVANCED GASTRIC CANCER
    Kim, Y. S.
    Sym, S. J.
    Park, I.
    Hong, J.
    Ahn, H. K.
    Park, J.
    Cho, E. K.
    Lee, W. K.
    Chung, M.
    Kim, H. S.
    Lee, J. H.
    Shin, D. B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E18 - E18
12345